Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation

Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old J...

Descripción completa

Detalles Bibliográficos
Autores principales: Makimoto, Go, Nishi, Tatsuya, Kawakado, Keita, Nishimura, Tomoka, Tamura, Tomoki, Kudo, Kenichiro, Kuyama, Shoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516312/
https://www.ncbi.nlm.nih.gov/pubmed/32461525
http://dx.doi.org/10.2169/internalmedicine.4429-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516312/
https://www.ncbi.nlm.nih.gov/pubmed/32461525
http://dx.doi.org/10.2169/internalmedicine.4429-20

Ejemplares similares